PT  - JOURNAL ARTICLE
AU  - Yu Ando
AU  - Marie Saito
AU  - Masakazu Machida
AU  - Chikako Noro
AU  - Masataka Takahashi
AU  - Masashi Toyoda
AU  - Akihiro Umezawa
TI  - Can human embryonic stem cell-derived stromal cells serve a starting material for myoblasts?
AID  - 10.1101/119693
DP  - 2017 Jan 01
TA  - bioRxiv
PG  - 119693
4099  - http://biorxiv.org/content/early/2017/03/23/119693.short
4100  - http://biorxiv.org/content/early/2017/03/23/119693.full
AB  - A large number of myocytes is necessary to treat intractable muscular disorders such as Duchenne muscular dystrophy with cell-based therapies. However, starting materials for cellular therapy products such as myoblasts, marrow stromal cells, menstrual blood-derived cells and placenta-derived cells have a limited lifespan and cease to proliferate in vitro. From the viewpoints of manufacturing and quality control, cells with a long lifespan are more suitable as a starting material. In this study, we generated stromal cells for future myoblast therapy from a working cell bank of human embryonic stem cells (ESCs). The ESC-derived CD105+ cells with extensive in vitro proliferation capability exhibited myogenesis and genetic stability in vitro. These results imply that ESC-derived CD105+ cells are another cell source for myoblasts in cell-based therapy for patients with genetic muscular disorders. Since ESCs are immortal, mesenchymal stromal cells generated from ESCs can be manufactured at a large scale in one lot for pharmaceutical purposes.